The global antibiotic resistance market is anticipated to reach US$ 15.32 billion by 2028; growing at a CAGR of 6.3% during the forecast period, 2021 – 2028.
Antibiotic resistance is a condition that occurs when the pathogens like bacteria & fungi develop the ability to minimize & kill the effects of the drugs designed to kill them i.e., the bacteria & fungi become immune to the drugs. This simply means that the drug has no effect on the bacteria & fungi and they continue to grow influentially. This condition is mostly developed by the excessive and uncontrolled use of antibiotics. Most of the antibiotics are sold at open drug stores without being prescribed by the physician and even some physicians prescribe antibiotics without proper diagnosis. All these factors give rise to the development of antibiotic resistance which further drives the market of antibiotic resistance products. Every year in the U.S., 2.8 million get infected with antibiotic-resistant bacteria or fungi, and more than 35,000 people die of antibiotic resistance. The risk of antibiotic-resistant infections cannot be completely avoided and people with chronic diseases are more likely to develop the condition. Antibiotic resistance is a threat to mankind because if the antibiotics stop working, our body loses the ability to treat the disease. Currently, there is no proper treatment for antibiotic resistance. Increasing antibiotic infections and the emergence of various drug-resistant pathogens are driving the market growth of antibiotic resistance. However, FDA–approved products like Clostridium difficile infection (CDI) was launched in 2018 by the ACX–362E pharmaceuticals are very efficient in the treatment of antibiotic resistance.
The increasing antibiotic infections, excessive antibiotic usage, expanding bacterial contamination, development of drug-resistant pathogens, and growing clinical developments of antibiotic resistance are the major factors that are fueling the market growth of antibiotic resistance. In addition, a rapid increment in infectious & chronic disease globally is also pouring the market growth.
However, the high costs of the treatment associated with the infections & antibiotic resistance and extended hospital stays hinder the growth of the global antibiotic resistance market.
The introduction of novel pipeline drugs, support from the government, and extensive R&D on antibiotic resistance projects are providing lucrative opportunities to the global market. In addition, a large number of active market players are investing in R&D to provide better results in antibiotic resistance. For example, Pfizer uses drugs by Astra Zeneca’s, Zavicefta, and Zinforo, which result in an expanded portfolio of antibiotics.
The global antibiotic resistance market is fragmented into Disease, Pathogen, Drug Class, and region. The disease segment is further sub-segmented into Blood Stream Infections (BSI), Complicated Urinary Tract Infection (cUTI), Clostridium difficile infections (CDI), Complicated Intra-Abdominal Infections (cIAI), Acute Bacterial Skin & Skin Structure Infections (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP), and Hospital-Acquired Bacterial Pneumonia/Ventilator (HABP/VABP). Pathogen segment is classified into Pseudomonas aeruginosa (Carbapenem-Resistant), Staphylococcus Aureus (Methicillin-Resistant), Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing), E. coli/K. pneumoniae (Carbapenem-Resistant), Enterococcus faecium (Vancomycin-Resistant), Haemophilus Influenzae (Ampicillin-Resistant), and Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant). Drug Class covers Lipoglycopeptides, Oxazolidinones, Cephalosporins, Tetracyclines, and Combination therapies.
The global antibiotic resistance market is segmented into North America, Europe, Asia-Pacific, and RoW. North America is further classified into U.S., Canada, and Mexico. Europe is further segmented into Germany, the U.K., France, Italy, Spain, Russia, and the rest of Europe. Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of APAC. The RoW includes South & Central America, the Middle East, and Africa. Currently, North America dominates the global antibiotic resistance market.
Prominent players of the global antibiotic resistance market are Allergan, Pfizer, Johnson & Johnson, Merck, GlaxoSmithKline, Novartis, Sanofi, and Melinta Therapeutics among others. In this market, biotech companies are involved more than pharmaceutical companies.
Market Segmentation and Scope of the Global Antibiotic Resistance Market